Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341419 · ClinicalTrials.gov registry record
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
A clinical trial of Pseudoxanthoma Elasticum and PXE, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 188
- Enrollment target
- 1
- Study location
NCT00341419 is a study of Pseudoxanthoma Elasticum and PXE that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 188 participants, above the 94-participant average among 3 other Pseudoxanthoma Elasticum trials with a reported enrollment target (100% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00341419, a study of Pseudoxanthoma Elasticum and PXE, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 188 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will characterize the gene mutations responsible for pseudoxanthoma elasticum (PXE) and correlate them with disease manifestations in males and females. PXE is an inherited disorder that affects the connective tissue in some parts of the body. Calcium and other minerals are deposited in the connective tissue, causing changes in the skin, eyes, cardiovascular system and gastrointestinal system. Some effects of PXE can cause serious medical problems, while others have less impact. Symptoms often appear earlier and are more severe in females than in males, but there is no way to predict how the disorder will progress in any given individual. Candidates for this study are recruited through PXE International, an organization that provides patient support and supports research on the disease. The organization collects biological samples and medical information on patients and family members to help further research on the disease. Families that have samples from the patient, both parents, and at least one sibling may be eligible for this study. Grandparents and extended family members may be included in certain instances. Participants provide a blood sample, a sample of cells scraped from the inside of the cheek (buccal cells) and a medical history. The samples are analyzed for gene variants and the findings are correlated with disease signs and symptoms. ...
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2005-02-16 |
| Est. Completion | 2013-05-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00341419
The ClinicalTrials.gov registry entry for NCT00341419 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 94-participant average among 3 other Pseudoxanthoma Elasticum trials with a reported enrollment target (100% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pseudoxanthoma Elasticum appearing as the primary indexed condition, and to 0 interventions.
NCT00341419 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00341419 about?
NCT00341419 is a clinical study titled "Genetic Analysis of Patients With Pseudoxanthoma Elasticum". This study will characterize the gene mutations responsible for pseudoxanthoma elasticum (PXE) and correlate them with disease manifestations in males and females. PXE is an inherited disorder that affects the connective tissue in some parts of the body. Calcium and other minerals are deposited in t...
What is the current status of trial NCT00341419?
This trial is currently completed. The enrollment target is 188 participants. The study started on 2005-02-16. Estimated completion is 2013-05-14.
What conditions does trial NCT00341419 study?
This clinical trial studies the following conditions: Pseudoxanthoma Elasticum, PXE.
Who is sponsoring clinical trial NCT00341419?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00341419 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pseudoxanthoma Elasticum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.